MedTrace Logo

Safety and Efficacy Study of Intramuscular Uricase-PEG 20

NCT01038947 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2009-12-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, pharmacokinetics and pharmacodynamics of single and multiple intramuscular doses of Uricase-PEG 20

Conditions

  • Gout
  • Hyperuricemia

Interventions

BIOLOGICAL

Uricase-PEG 20

Intramuscular injection of Uricase-PEG 20 without premedication

Sponsors & Collaborators

  • EnzymeRx

    lead INDUSTRY

Principal Investigators

  • Anthony S Fiorino, MD, PhD · EnzymeRx, LLC

  • Patricia Pardo, MD · MRA Clinical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-04-30
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038947 on ClinicalTrials.gov